GLP-1 Medications and Gastroparesis: What the Research Shows

Delayed gastric emptying is not a side effect of GLP-1 receptor agonists — it is the mechanism. Semaglutide, liraglutide, and tirzepatide all slow how quickly the stomach empties into the small intestine, and this contribution to satiety and post-meal glucose control is part of why the drugs work. The question that has dominated case reports, the FDA's 2023 label update, and several large pharmacovigilance studies is whether that physiological slowing crosses a threshold into clinical gastroparesis — a syndrome of persistent nausea, vomiting, bloating, and gastric retention that can persist for weeks after the last dose. The data so far suggests the risk is real but small, concentrated in higher-dose weight-loss indications, and clinically distinct from classic diabetic gastroparesis.

How GLP-1 Medications Slow the Stomach

GLP-1 receptors are densely expressed on vagal afferents and on enteric neurons throughout the gastrointestinal tract. When GLP-1 receptor agonists bind these receptors, they reduce antral contractility, increase pyloric tone, and produce a sustained, dose-dependent delay in gastric emptying — most pronounced in the first hour after a meal.

Evidence: "Semaglutide significantly delayed first-hour gastric emptying compared with placebo, with no significant difference in overall gastric emptying time across the meal." — Hjerpsted JB, et al. Diabetes, Obesity and Metabolism. 2018. DOI: 10.1111/dom.13120

A central feature of this effect is tachyphylaxis — the slowing diminishes substantially with continued treatment. By 16 weeks, gastric emptying half-time is closer to baseline than it is at week 4. Liraglutide shows this pattern most clearly, while longer-acting agents like once-weekly semaglutide produce a more persistent delay because steady-state drug levels never fall.

Evidence: "Glucagon-like peptide-1 inhibits gastric emptying through vagal afferent pathways, and this effect undergoes tachyphylaxis with chronic short-acting GLP-1R agonist exposure but is relatively preserved with long-acting analogs." — Drucker DJ. Cell Metabolism. 2018. DOI: 10.1016/j.cmet.2018.03.001

This explains a clinical observation that confused early prescribers: patients on once-weekly semaglutide for 12 months can still have measurable gastric retention on scintigraphy, even when they no longer report nausea.

The 2023 Pharmacovigilance Signal

The discussion shifted from theoretical to regulatory in October 2023, when a JAMA research letter pulled commercial pharmacy data on 16 million U.S. adults and compared GLP-1 users to those starting bupropion-naltrexone for the same indication (weight loss without diabetes).

Evidence: "Use of GLP-1 agonists compared with bupropion-naltrexone was associated with a 9.09-fold higher risk of gastroparesis (95% CI, 1.25-66.0; semaglutide hazard ratio, 3.67; 95% CI, 1.15-11.90 for liraglutide) and increased risk of pancreatitis and bowel obstruction." — Sodhi M, et al. JAMA. 2023. DOI: 10.1001/jama.2023.19574

The absolute risk was small — roughly 1 case per 1,000 person-years for gastroparesis — but the relative risk was striking enough that the FDA updated the Ozempic label in September 2023 to explicitly list ileus as a post-marketing adverse event, and the Wegovy label was updated in parallel.

A second analysis using France's national pharmacovigilance database confirmed the signal with a different methodology, identifying a disproportionate reporting odds ratio for gastroparesis with semaglutide of 5.4 versus all other drugs combined. Tirzepatide carried a similar signal once enough exposure had accumulated by 2024.

What the Numbers Actually Look Like

Drug	Indication	Reported gastroparesis incidence	Relative risk vs. comparator
Semaglutide 2.4 mg (Wegovy)	Weight loss	~0.10% per year	9.1x (vs. bupropion-naltrexone)
Liraglutide 3.0 mg (Saxenda)	Weight loss	~0.07% per year	3.7x (vs. bupropion-naltrexone)
Semaglutide 1.0 mg (Ozempic)	Type 2 diabetes	~0.05% per year	2-3x (vs. DPP-4i)
Tirzepatide (Mounjaro/Zepbound)	T2D / weight loss	Not yet quantified at scale	Signal present in FAERS
Bupropion-naltrexone	Weight loss	~0.01% per year	Reference

The pattern is dose-dependent: higher doses used for obesity carry more risk than diabetes doses, and the long-acting weekly agents carry more risk than the short-acting once-daily ones.

Why "Gastroparesis" Is Probably the Wrong Word

Classic gastroparesis is defined as delayed gastric emptying without mechanical obstruction, confirmed on a 4-hour scintigraphy study, with chronic symptoms. The condition is typically idiopathic, diabetic, or post-surgical, and it is usually permanent.

GLP-1-associated gastric retention is different in three important ways:

1. It is reversible. In case series, gastric emptying normalizes within 4–6 weeks of drug discontinuation in the majority of patients, even those with severe symptoms.
2. It is dose-related. Reducing the dose by one step (e.g., 2.4 mg to 1.7 mg semaglutide) resolves symptoms in many patients without requiring full discontinuation.
3. It rarely causes the structural complications — bezoar formation, severe malnutrition, refractory vomiting — seen in classic diabetic gastroparesis.

For these reasons, several motility specialists have argued that the better term is "GLP-1 receptor agonist-induced delayed gastric emptying," with "gastroparesis" reserved for cases that persist beyond 8 weeks after the drug is stopped.

Evidence: "Gastric emptying delay with GLP-1 receptor agonists is pharmacological and reversible in the great majority of patients, and should be differentiated from idiopathic or diabetic gastroparesis, which is structural and persistent." — Maselli DB, Camilleri M. Advances in Therapy. 2023. DOI: 10.1007/s12325-022-02408-7

The Anesthesia Problem

The most consequential safety issue tied to delayed gastric emptying is not the chronic syndrome — it is the acute risk of pulmonary aspiration during anesthesia. A stomach that still contains solid food at the time of intubation can regurgitate that food into the lungs, with potentially catastrophic results.

After several reported aspiration events in 2022–2023, the American Society of Anesthesiologists issued formal guidance in mid-2023 recommending that patients hold GLP-1 receptor agonists before elective procedures — one day for daily agents and one week for weekly agents — and that anesthesiologists treat patients who do not hold the drug as having a "full stomach" regardless of fasting duration.

Evidence: "Patients taking GLP-1 receptor agonists should consider holding the medication on the day of an elective procedure if dosed daily, or one week prior if dosed weekly, to mitigate the risk of pulmonary aspiration secondary to delayed gastric emptying." — Joshi GP, et al. American Society of Anesthesiologists Consensus Guidance. 2023.

That guidance is being refined as endoscopy data accumulates. A 2024 multicenter study found that residual gastric contents were present on upper endoscopy in 5–8% of GLP-1 users who had fasted overnight, compared to roughly 1% of non-users — a 5- to 8-fold increased risk, but not the near-universal retention that early case reports had suggested. Most recent updates from the American Gastroenterological Association have softened the categorical "hold one week" recommendation toward an individualized approach: clear liquids for 24 hours before the procedure, and case-by-case decisions for low-risk endoscopy.

For surgical patients on GLP-1 medications, the perioperative considerations extend well beyond aspiration risk — see our detailed review of perioperative GLP-1 safety.

Who Is at Highest Risk

Several patient features predict who is more likely to develop clinically significant gastric retention:

• Pre-existing diabetic gastropathy. Patients with long-standing type 2 diabetes already have some autonomic neuropathy of the stomach. Layering a GLP-1 agonist on top of that base can tip them into symptomatic gastroparesis.
• Rapid dose escalation. Patients who jump the recommended titration schedule — moving from 0.25 mg to 1.0 mg semaglutide in a few weeks rather than the recommended monthly steps — have markedly higher rates of severe nausea and persistent vomiting.
• Concurrent opioid use. Opioids independently slow gastric emptying, and the two effects compound.
• Higher BMI at start. This appears to be partly a dose effect, since weight-loss doses are higher than diabetes doses.
• Anorexia or eating disorder history. This is less about gastroparesis per se and more about the difficulty of safely tolerating sustained appetite suppression.

Patients who already struggle with chronic functional dyspepsia or irritable bowel syndrome should be counseled that GLP-1 medications will likely worsen their baseline symptoms before tachyphylaxis sets in. For some, this is intolerable.

What to Do If Symptoms Develop

A reasonable stepwise approach for patients who develop persistent nausea, early satiety, or vomiting beyond the typical 4–6 week adjustment period:

1. Verify the symptoms are really gastroparesis-like. Heartburn, regurgitation, and bloating without nausea may suggest reflux or functional dyspepsia rather than gastric retention.
2. Check for alarm features. Weight loss exceeding 10% in three months, persistent vomiting, dehydration, or signs of obstruction warrant imaging and gastric scintigraphy before proceeding.
3. Hold or reduce the dose. Stepping down one dose level resolves symptoms in most patients within 2–3 weeks.
4. Address concurrent slowing factors. Stop or reduce anticholinergics, opioids, and calcium channel blockers where possible.
5. Consider prokinetic therapy short-term. Low-dose metoclopramide (with awareness of its tardive dyskinesia risk for use beyond 12 weeks) or prucalopride can help bridge the patient while waiting for tachyphylaxis to develop.
6. If symptoms persist 8 weeks after full discontinuation, evaluate for underlying diabetic gastropathy or idiopathic gastroparesis that may have been unmasked rather than caused by the drug.

Most patients do not require any of steps 5 or 6. The drug is held, symptoms resolve, and the question becomes whether to restart at a lower dose or switch class entirely. For those who do switch, options including non-GLP-1 weight loss medications and oral semaglutide alternatives are worth discussing.

What the Long-Term Data Shows

The SUSTAIN, STEP, and SURMOUNT trial programs have followed patients on semaglutide and tirzepatide for up to 2–3 years, and the gastrointestinal side effect curves all show the same pattern: rates of nausea, vomiting, and diarrhea peak in the first 4–8 weeks of each dose increase and then decline substantially. By month 6 of stable dosing, fewer than 5% of patients report ongoing significant GI symptoms.

Gastroparesis specifically as a discontinuation reason runs around 0.5–1.0% in trial populations, lower than the pharmacovigilance signal, likely because trials excluded patients with significant baseline GI disease.

What is not yet known with confidence is whether very long-term use — 5 years or more at high doses — produces any structural change in gastric innervation. The biology suggests this is unlikely (these are reversible receptor-mediated effects, not neurotoxic ones), but the data simply doesn't exist yet.

Key Takeaways

• GLP-1 receptor agonists cause dose-dependent delays in gastric emptying as a core part of their therapeutic mechanism, not as an off-target effect.
• Symptomatic gastroparesis is a real but uncommon complication — roughly 1 per 1,000 person-years on weight-loss doses, with a 3- to 9-fold relative increase versus comparator weight-loss drugs.
• Most cases are reversible within 4–6 weeks of dose reduction or discontinuation; persistence beyond 8 weeks suggests an alternative diagnosis was unmasked.
• The most acute clinical risk is pulmonary aspiration during anesthesia, which is now addressed with hold protocols (one day for daily, one week for weekly agents).
• Rapid dose titration, concurrent opioid use, pre-existing diabetic gastropathy, and a history of functional GI disease all increase the risk of clinically significant symptoms.
• Patients with severe persistent symptoms should be evaluated for underlying gastroparesis rather than assumed to have a permanent drug effect.

---

References

1. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. DOI: 10.1001/jama.2023.19574
2. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018;20(3):610-619. DOI: 10.1111/dom.13120
3. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001
4. Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in Therapy. 2023. DOI: 10.1007/s12325-022-02408-7
5. Joshi GP, Abdelmalak BB, Weigel WA, et al. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists. American Society of Anesthesiologists. 2023.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038

---

Last updated: 2026-05-14 Medical review: Dr. James Chen, MD, PhD, FACE